MERIT MEDICAL SYSTEMS INC Q3 FY2026 earnings call

• Growth Momentum: Delivered 9% organic constant currency growth in Q3, exceeding high-end expectations and continuing the trend from Q2. Growth was balanced across foundational (8%) and therapeutic (11%) categories.
• Strategic Acquisitions & Integration: Continued integration of Viewpoint Medical into the oncology platform is progressing well, with strong pipeline evaluations for OneMark. Completed acquisition of Solopace for ~$45 million to expand cardiac therapies (TAVR pacing), leveraging prior exclusive distribution rights.
• Clinical Progress: Presented data from the Rhapsody Global Registry at CETA; strengthened clinical evidence for CTIF (esophix) in GERD treatment showing non-inferiority to surgery with lower dysphagia rates.
• Leadership Transition: Sherry Lewis joined as COO, focusing on integrated business planning, working capital efficiency, and operational excellence. Neil Peterson stepped down as COO after 32 years, serving as Senior Advisor through March 2027.
• Strategic Planning: Finalizing multi-year strategic plan (2027-2029) focusing on high-growth procedures and portfolio expansion. An investor event is scheduled for February 11, 2027, to present new financial targets.
• Operational Excellence: Maintained discipline on operating expenses despite gross margin pressure from manufacturing variances (platinum costs) and freight.

Total revenue was $416 million, an 8% year-over-year increase on a GAAP and constant currency basis. Foundational products contributed to the growth with $14 million in sales increases (6% GAAP, 8% organic). Therapeutic products showed stronger momentum with $17 million in sales increases (13% GAAP, 11% organic). The company delivered strong profitability, with non-GAAP operating margin increasing 160 basis points year-over-year to 21.3%. Non-GAAP EPS rose 22% year-over-year to $1.12, and free cash flow generation was nearly $53 million.

• FY 2026 Revenue: Updated total GAAP net revenue growth guidance to 7.9%-8.4% YoY (7%-7.5% constant currency).
• FY 2026 EPS: Raised non-GAAP diluted EPS guidance to $4.33-$4.37 (previously $4.25-$4.35), reflecting expected 13%-14% growth.
• FY 2026 Operating Margin: Expects non-GAAP operating margin of 21.2%-21.4%, up 94-116 basis points YoY.
• Q4 2026 Revenue: Expects total revenue of $418-$426 million (6%-8% YoY growth).
• Q4 2026 Profitability: Expects non-GAAP operating margins of 21.2%-22.1% and non-GAAP EPS of $1.08-$1.12.
• Three-Year CGI Targets: Confirmed targets for organic constant currency revenue CAGR of 5%-7%, non-GAAP operating margin of 20%-22%, and cumulative free cash flow >$400 million by end of 2026.

• China Market Dynamics: Facing headwinds from Volume-Based Procurement (VBP) and government crackdowns encouraging local procurement. Management reduced China outlook slightly (~$4 million for H2) but remains confident in long-term potential, noting APAC growth excluding China was strong (6%).
• Tariffs: Tariff impacts remain a concern; management expects ~$1.3 million in refunds from vendors but maintains a ~$60 million annual headwind assumption in guidance. Section 232 regulations are being monitored.
• Competitive Pressure: Significant competitive responses observed in the Rhapsody market, including competitor hiring and aggressive tactics, validating product strength but indicating a difficult battle for market share.
• Gross Margin Volatility: Suffered 81 bps YoY decline due to manufacturing variances (platinum raw materials), bonus true-ups, and higher freight costs, though offset by operating expense leverage.

Q: Analyst asked if the current high single-digit organic growth rate is sustainable or if there are levers to sustain performance against tougher comps.

A: CEO Martha Aronson emphasized that the growth is balanced across platforms, providing confidence for the rest of the year. She declined to comment on specific future years but noted the team's focus on executing quarterly goals and preparing for the February investor event where longer-term strategies will be shared. She highlighted pride in the team's consistent delivery.

Q: Analyst asked about the impact of tariffs on gross margin and updates on tariff refunds/headwinds.

A: CFO Raul Parra stated tariffs were not significant to the recent gross margin decline, which was driven by platinum variances, bonuses, and freight. He confirmed expecting ~$1.3 million in vendor refunds, likely arriving in early next year. He reiterated that the company has not changed its annual tariff headwind assumption of ~$60 million included in guidance.

Q: Analyst questioned the rationale behind the SoloPace acquisition timing relative to the TAVR National Coverage Decision (NCD) and revenue scale.

A: CEO Aronson clarified that the NCD was not a driver for the transaction timing; rather, it was a natural progression after years of exclusive distribution and strategic investment. She noted the deal is immaterial to 2026 but slightly accretive to 2027 earnings, expanding their structural heart portfolio with technologies that simplify TAVR workflows.

Q: Analyst asked about the competitiveness of the Rhapsody product and any updates on its $7 million revenue guide.

A: CEO Aronson reported that physicians are highly impressed with the technology, but competition is fierce, with rivals hiring aggressively and responding traditionally. She validated the product's clinical strength through this competitive response and mentioned upcoming data presentations at the CETA conference to further support the clinical narrative.

Q: Analyst inquired about the China market outlook, specifically regarding VBP and anti-corruption dynamics, and if the strategy is shifting.

A: CEO Aronson described the situation as tough but not new, noting increased scrutiny on foreign education sponsorship. CFO Parra added that international growth excluding China was strong (6%), hedging against China risks. They are exploring 'made-in-China-for-China' pilots but maintain confidence in the market's long-term potential, attributing recent challenges to 'noise' rather than fundamental shifts.